Toggle light / dark theme

The number of people suffering from osteoarthritis is expected to top 1 billion by 2050. The biggest risk factor for the prevalent, often painful, chronic joint disease is aging. And like aging, there is currently no way to stop it.

A discovery by scientists at Henry Ford Health + Michigan State University Health Sciences could pave the way for new breakthroughs in detecting and treating the disease. Their findings were recently published in Nature Communications.

“Our hope is that this discovery will one day allow doctors to catch the disease earlier and intervene before significant joint damage occurs,” said Shabana Amanda Ali, Ph.D., a Henry Ford Health assistant scientist and senior author of the paper. “Osteoarthritis is so complex and so heterogeneous that even with decades of research there hasn’t been a single therapeutic.”

Thyroid eye disease (TED; also known as Graves’ orbitopathy), causes swollen extraocular muscles and orbital fat. Mechanistically, TED involves lid retraction, oedema and redness of the eyelids and conjunctiva, proptosis, diplopia, and optic neuropathy. Investigation of TED involves assessment of disease activity (inflammation) and disease severity. TED is predominantly mild in 77% of cases, moderate-to-severe in 22%, and rarely sight-threatening in 1% of patients. While most patients with TED have Graves’ hyperthyroidism, up to 5% are euthyroid or even hypothyroid.

Our eyes could potentially be coaxed into a special repair mode above and beyond our natural self-healing abilities, according to a new study, thanks to the delivery of antibodies that trigger nerve cell regeneration in the retina.

The South Korean research team says the treatment offers hope for restoring lost vision that otherwise can’t be brought back. For now though, it’s only been tested in mice.

Here’s how it works: a compound antibody drug is used to block the prospero homeobox protein 1 (Prox1). This protein isn’t inherently bad, playing an important role in cell regulation, but it appears to stop retinal nerves from regenerating.

Photographer Stephen Voss has been working on a project about data centers and recently travelled to Abilene, Texas to document the first data center built as part of the Stargate Project. When completed, it will be the largest data center in the world. Here’s a short drone video he took of the project:

“The place was mesmerizing and deeply unsettling,” Voss told me over email. “When finished, it’ll have the power demands of a mid-sized city and is on a piece of land that’s the size of Central Park.”

Nicotinamide adenine dinucleotide (NAD) is a ubiquitous electron carrier essential for energy metabolism and post-translational modification of numerous regulatory proteins. Dysregulations of NAD metabolism are widely regarded as detrimental to health, with NAD depletion commonly implicated in aging. However, the extent to which cellular NAD concentration can decline without adverse consequences remains unclear. To investigate this, we generated a mouse model in which nicotinamide phosphoribosyltransferase (NAMPT)-mediated NAD+ biosynthesis was disrupted in adult skeletal muscle. The intervention resulted in an 85% reduction in muscle NAD+ abundance while maintaining tissue integrity and functionality, as demonstrated by preserved muscle morphology, contractility, and exercise tolerance. This absence of functional impairments was further supported by intact mitochondrial respiratory capacity and unaltered muscle transcriptomic and proteomic profiles. Furthermore, lifelong NAD depletion did not accelerate muscle aging or impair whole-body metabolism. Collectively, these findings suggest that NAD depletion does not contribute to age-related decline in skeletal muscle function.

#Aging #Longevity aging and longevity.


NAD depletion in skeletal muscle does not impair tissue integrity and function or accelerate aging, as shown in a mouse model with an 85% decrease in muscle NAD+ levels. Muscle structure, metabolism, and mitochondrial function remain unaffected, suggesting that NAD depletion does not drive age-related muscle decline.

Featuring the Electro-Mechanical Brake and by-wire technology on the rear brakes, the project will also include ZF’s Integrated Brake Control and traditional front calipers, creating a ‘hybrid’ braking system of by-wire and hydraulics that offers increased flexibility to the manufacturer. The agreement will also provide significant steering technology with ZF’s Electric Recirculating Ball Steering Gear. This cutting-edge braking technology combined with traditional braking systems and innovative steering tools further solidifies ZF’s position as the industry leader in providing complete chassis solutions to its customers while providing a major customer win.

“We are all proud to see ZF’s technology leadership in the Chassis segment providing tangible value for our customers. Our goal when combining our steering, braking, dampers and actuators as well as corresponding software businesses into a single division was to create the world’s most comprehensive Chassis Solutions product and system offering,” said Peter Holdmann, Board of Management member at ZF and head of Division Chassis Solutions. “This combined center of expertise allows us to offer comprehensive solutions that integrate advanced engineering, innovative design, and cutting-edge technology to deliver unparalleled performance and safety.”

The road to the software-defined vehicle With the Electro-Mechanical Brake (EMB) as a key component of the brake-by-wire technology, ZF lays the foundation for the software-defined vehicle that will lead to new functions and features, many that emphasize safety as much as driving comfort. One such feature being explored with by-wire technology is the ability for the vehicle to autonomously brake and steer in a crash situation.


ZF’s Electro-Mechanical Brake provides premium performance for automatic emergency braking, full energy recuperation and redundant fallback options up to full automated driving for passenger car and light truck segments.